Clinical trials: In-stent Restenosis
Coronary Disease, Coronary Artery Disease
ABSORB Clinical Investigation, Cohort A (ABSORB A) Everolimus Eluting Coronary Stent System Clinical Investigation
Prospective, open-labeled First in Man Clinical Investigation enrolling patients with visually estimated nominal vessel diameter of 3.0 mm receiving a single 3.0 x 12 mm or 3.0 x 18 mm BVS EECSS containing 98 microgramme per cm²…
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ABSORB A (NCT00300131)
- Testing
- Bioabsorbable Everolimus Eluting Coronary Stent
- Where
- 4 sites in Denmark, Netherlands and 2 more
- Volunteers
- 30 people
- Sponsor
- Abbott Medical Devices
Peripheral Vascular Disease
Paclitaxel Eluting Balloon and Conventional Balloon for In-Stent Restenosis of the Superficial Femoral Artery
The aim of this study is to perform a randomized, controlled trial to compare percutaneous transluminal angioplasty using paclitaxel eluting balloon (PEB) or using a conventional balloon for treatment of superficial femoral…
- Trial name
- ISAR-PEBIS (NCT01083394)
- Testing
- PTA, PTA with PEB, Percutaneous Transluminal Angioplasty (PTA)
- Where
- 2 sites in Germany
- Volunteers
- 70 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Disease, Coronary Artery Disease
To Study the Safety and Clinical Outcomes of the Absorb Bioresorbable Vascular Scaffold (BVS) System in Patients With de Novo Lesions in Previously Untreated Vessels
The purpose of this study is to determine the safety and clinical outcomes of the Absorb BVS for daily use in patients with de novo lesions in previously untreated vessels.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ABSORB UK (NCT01977534)
- Testing
- Absorb BVS
- Where
- 24 sites in United Kingdom
- Volunteers
- 1,005 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Cost-Effectiveness Study in the Reduction of Coronary Restenosis With Sirolimus-Eluting Stents
Since the advent of coronary stents, in-stent restenosis has proven to be the major limitation of interventional cardiology, occurring in as many as 30% of patients.
- Trial name
- GERSHWIN (NCT00627900)
- Testing
- bare metal stent, Cypher-Stent (Implantation of a sirolimus-eluting stent)
- Where
- Germany
- Volunteers
- 958 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Coronary Artery Disease, Coronary Restenosis
The SCRIPPS DES REAL WORLD Registry
This study is a prospective, non-randomized, open-label registry of consecutive patients with CAD treated by stent-assisted PCI using at least one CypherTM stent. Up to 1000 pts will be included in the registry.
- Conditions
- Coronary Artery Disease, Coronary Restenosis, Coronary Thrombosis
- Trial name
- NCT00714623
- Testing
- Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)
- Where
- United States
- Volunteers
- 859 people
- Sponsor
- Paul S Teirstein, MD
Coronary Artery Disease, Restenosis of Coronary Artery Stent
Oral Colchicine in Argentina to Prevent Restenosis
The Oral treatment of Colchicine in Argentina (ORCA) trial is a prospective, randomized, multicenter trial to included 450 patients with indication for myocardial revascularization with PCI between a group to be treated with BMS…
- Conditions
- Coronary Artery Disease, Restenosis of Coronary Artery Stent, Atherosclerosis, Acute Coronary Syndrome
- Trial name
- ORCA (NCT04382443)
- Testing
- Colchicine
- Where
- 2 sites in Argentina
- Volunteers
- 410 people
- Sponsor
- Centro de estudios en Cardiologia Intervencionista
de Novo, Symptomatic Ischemic Heart Disease
BIOFLOW-SV All Comers Registry
Assessment of the clinical safety and performance of the Orsiro drug-eluting stent in a real world setting in patients with small vessels with reference vessel diameter ≤2.75 mm.
- Conditions
- de Novo, Symptomatic Ischemic Heart Disease, Restenoses, Coronary
- Trial name
- BIOFLOW-SV (NCT03600948)
- Testing
- Orsiro Sirolimus Eluting Coronary Stent System
- Where
- 2 sites in Brazil
- Volunteers
- 261 people
- Sponsor
- Biotronik AG
Peripheral Arterial Disease
Outcomes of Endovascular Treatment of Superficial Femoral Artery In-stent Restenosis
Lower limb peripheral arterial disease (PAD) is a common, important manifestation of systemic atherosclerosis. Stenosis or occlusions in the superficial femoral artery (SFA) may result in intermittent claudication or even…
- Trial name
- NCT04123639
- Testing
- PTA
- Where
- Egypt
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Assiut University
Coronary Disease, Coronary Artery Disease
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries.
- Conditions
- Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Trial name
- ZoMaxx™ I (NCT00148356)
- Testing
- ZoMaxx™ Drug-Eluting Coronary Stent System, TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System
- Where
- 29 sites in Australia, Belgium and 8 more
- Volunteers
- 401 people
- Sponsor
- Abbott Medical Devices
In-stent Restenosis
Comparing the Safety and Efficacy of Paclitaxel Controlled Release Balloon Catheter in the Treatment of In-stent Restenosis of Coronary Artery Lesion With Paclitaxel Release Coronary Balloon Catheter
Study purpose The safety and efficacy of paclitaxel controlled release balloon catheter Vasoguard TM in treatment of in-stent restenosis.
- Trial name
- NCT02891018
- Testing
- paclitaxel controlled release balloon catheter Vasoguard TM, paclitaxel release coronary balloon catheter SeQuent Please
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Shandong Branden Med.Device Co.,Ltd
In-stent Arterial Restenosis
Paclitaxel Eluting Balloon for SFA In-stent Restenosis
The purpose of the study is to evaluate the safety and efficacy on the use of drug eluting balloon (DEB) with paclitaxel to treat in-stent restenosis in femoropopliteal arteries.
- Trial name
- NCT01616888
- Testing
- PTA with drug eluting balloon with paclitaxel
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
In-stent Restenosis, Major Adverse Cardiovascular Events
Effect of Evolocumab on Chronic Total Occlusions (EVOLO-CTO)
The purpose of this study is to evaluate the effect of proprotein convertase subtilisin/kexin type-9 (PCSK9) inhibitors added to regular statin therapy on target lesion failure (TLF) and arteriosclerosis progression in patients…
- Trial name
- NCT05623995
- Testing
- PCSK9 inhibitor, Statin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Lin Zhao
Stent Thrombosis, Restenosis
Prospective Clinical Observational Registry Including Consecutive Patients With In-stent Restenosis or Stent Thrombosis
Prospective clinical observational registry study including consecutive patients with clinical signs or symptoms due to in-stent restenosis (ISR) or definite (ARC criteria) stent thrombosis (ST).
- Trial name
- NIVUS (NCT00647504)
- Where
- 5 sites in Denmark, Finland and 3 more
- Volunteers
- 450 people
- Sponsor
- Tampere University
Peripheral Pulmonary Stenosis, In-stent Stenosis
Systemic Rapamycin (Sirolimus) to Prevent In-Stent Restenosis Following Pulmonary Artery Stent Placement
This is a research study to assess whether an oral medication can benefit some patients being treated for peripheral pulmonary stenosis (PPS), which is narrowing of the blood vessels that send blood to the lungs (pulmonary…
- Trial name
- NCT02365415
- Testing
- Sirolimus
- Where
- United States
- Sponsor
- Boston Children's Hospital
Angioplasty, Cardiovascular Disease
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
Abbott Vascular (AV) obtained marketing approval for the XIENCE PRIME Everolimus Eluting Coronary Stent System (XIENCE PRIME EECSS) in China from the China Food and Drug Administration (CFDA) on August 10th, 2011.
- Conditions
- Angioplasty, Cardiovascular Disease, Coronary Artery Disease, Coronary Heart Disease
- Trial name
- XP China SAS (NCT01894152)
- Testing
- XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
- Where
- United States
- Volunteers
- 2,002 people
- Sponsor
- Abbott Medical Devices
In Stent Restenosis
Focal In-stent Restenosis After Drug-Eluting Stent
To evaluate the optimal management of focal in-stent restenosis after drug-eluting stent implantation with sirolimus-eluting implantation versus cutting balloon angioplasty
- Trial name
- FOCUS (NCT00485004)
- Testing
- Cutting balloon, Sirolimus-eluting stent
- Where
- 15 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
SONICURE（SONICracker for the Treatment of UndeRExpansion）
The first-phase study is a prospective, single-group observational study. It plans to recruit patients with in-stent restenosis caused by poor stent expansion in the coronary artery.
- Trial name
- NCT06924736
- Testing
- Intravascular Shockwave Therapy Device / Disposable Coronary Shockwave Catheter, Non - compliant balloon dilatation catheter
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Acute Coronary Syndrome, Angina Pectoris
DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population
The introduction of drug-eluting stents (DES) in the treatment of coronary artery disease has led to a significant reduction in morbidity but there are further demands on DES performance.
- Conditions
- Acute Coronary Syndrome, Angina Pectoris, Angina, Unstable, Myocardial Infarction
- Trial name
- DUTCH PEERS (NCT01331707)
- Testing
- Resolute Integrity (Zotarolimus-eluting stent), Promus Element (Everolimus-eluting stent)
- Where
- 4 sites in Netherlands
- Volunteers
- 1,811 people
- Sponsor
- Foundation of Cardiovascular Research and Education Enschede
Coronary Heart Disease
The Comparative Study of OCT，Gemstone CT and 320-detector Row Spiral CT for Evaluating Restenosis of Coronary Artery Stent
In-stent restenosis is a major reason of coronary heart disease recurrence .Even in drug eluting stent(DES), Restenosis rate could be up to 10% in diabetes and complex lesions though it was about 3-5% in general.
- Trial name
- NCT02219594
- Testing
- CT image for patient with suspected in-stent restenosis
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Xuzhou Central Hospital
Peripheral Arterial Disease
Drug Eluting Balloon in Peripheral Intervention for In-Stent Restenosis
The purpose of this study is to evaluate the efficacy of drug-eluting balloon angioplasty followed versus conventional balloon angioplasty in superficial femoral artery and popliteal artery re-stenosis.
- Trial name
- DEBATE-ISR (NCT01558531)
- Testing
- DEB, POBA
- Where
- Italy
- Volunteers
- 44 people
- Sponsor
- Leonardo Bolognese, MD